NCT06428487View on ClinicalTrials.gov

Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions

Colorectal Cancer

Interventions

DRUG

Prolgolimab

Prolgolimab infusions 1 mg/kg

Trial Locations (1)

Unknown

RECRUITING

N.N. Blokhin NMRCO, Moscow

All Listed Sponsors

lead

Blokhin's Russian Cancer Research Center

OTHER